Peptide Schedule
Matrixyl 30007 residues (approx.)GHKGQPREach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.Matrixyl 3000 Dosage Calculator
Matrixyl 3000 is a patented dual-peptide complex developed by Sederma that combines Palmitoyl Tripeptide-1 (Pal-GHK, MW 578.8 Da) and Palmitoyl Tetrapeptide-7 (Pal-GQPR, MW 694.9 Da) to address skin aging through two complementary mechanisms.
2mcg · Daily
Summary: Add 0mL BAC water to your 5mg vial. Draw to < 0.1 units on a U-100 syringe for a 2mcg dose. This vial will last 0 doses.
Cycle Planner
Matrixyl 3000 Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~6 hours (topical; no systemic PK data)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Matrixyl 3000 Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 2mg | Daily |
| Moderate | 5mg | 2x Daily |
| Aggressive | 10mg | 2x Daily |
Note: Topical anti-aging peptide complex developed by Sederma (patent WO 2005/048968). Contains two matrikine peptides: Palmitoyl Tripeptide-1 (Pal-GHK) and Palmitoyl Tetrapeptide-7 (Pal-GQPR). Distinct from the original Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS) — Matrixyl 3000 uses a dual-peptide approach combining collagen stimulation with anti-inflammatory action. Typical serum concentrations range from 3-8% of the Matrixyl 3000 complex. Dosing tiers above reflect approximate mg of combined active peptides per topical application. Apply to clean, dry skin targeting periorbital wrinkles, forehead lines, and nasolabial folds.
About Matrixyl 3000
Matrixyl 3000 is a patented dual-peptide complex developed by Sederma that combines Palmitoyl Tripeptide-1 (Pal-GHK, MW 578.8 Da) and Palmitoyl Tetrapeptide-7 (Pal-GQPR, MW 694.9 Da) to address skin aging through two complementary mechanisms. Palmitoyl Tripeptide-1 is a lipidated derivative of the GHK fragment found in type I collagen — the same tripeptide backbone as GHK-Cu but conjugated to palmitic acid instead of copper. It functions as a matrikine signaling molecule that activates fibroblast matrix receptors, upregulating synthesis of collagen types I, III, IV, and VII, as well as fibronectin and glycosaminoglycans including hyaluronic acid. Palmitoyl Tetrapeptide-7 is derived from a fragment of immunoglobulin G and targets the inflammatory component of skin aging by inhibiting interleukin-6 (IL-6) secretion from keratinocytes, reducing chronic low-grade inflammation (inflammaging) that accelerates collagen degradation. Both peptides are N-acylated with a 16-carbon palmitic acid chain to enhance lipophilicity and penetration through the stratum corneum. In manufacturer-sponsored double-blind clinical trials, twice-daily application of 3% Matrixyl 3000 cream for 2 months reduced the surface area occupied by deep wrinkles by 45%, increased skin tonicity by nearly 20%, and decreased wrinkle volume by 17.1% in male subjects. A six-month study reported up to 68% reduction in deep wrinkle surface area and 46% decrease in wrinkle density. In vitro, the combination stimulated collagen I production by 117%, collagen IV by 327%, and glycosaminoglycan synthesis by 287% compared to controls. A 2024 clinical trial of an eye cream containing palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7 showed a 54.99% increase in collagen production and 18.81% improvement in elasticity over 12 weeks, with mRNA upregulation of Col I (1.8x), Col III (2.5x), Col IV (2.8x), elastin (5.0x), and fibronectin (1.6x). The Cosmetic Ingredient Review (CIR) Expert Panel assessed tripeptide-1, its fatty acyl derivatives, and palmitoyl tetrapeptide-7 as safe for use in cosmetics at current concentrations (typically <10 ppm for individual peptides). Matrixyl 3000 is not FDA-approved for any medical indication and remains a cosmeceutical ingredient with strong in vitro data and moderate clinical evidence from manufacturer-sponsored and independent trials.